CAP
CMS Final Pricing for Genomic Procedure Codes Leaves Lab, Industry Stakeholders Wanting More
Premium
After going through the gapfill process and releasing final pricing for six codes related to genomic sequencing procedures, the final pricing still has stakeholders worried.
Despite Broad Carve-Outs, FDA Final Rule on LDTs Draws Critical Response From Lab Industry
The rule makes explicit that LDTs are subject to FDA oversight but provides for enforcement discretion across a broad range of tests.
The projects signal ongoing concern among health regulators about the quality and regulation of lab-developed tests used to guide cancer treatment and gauge disease risk.
AMP, CAP Release Guidelines for Use of In Silico Approaches for Validating NGS Data Pipelines
Labs should not let in silico data supplant physical specimens in bioinformatic validation and should understand the limitations of such data.
If the Center for Genomic Interpretation's in silico quality assessment catches on with payors, some labs are sure to push back or propose data sharing as an alternative.